Home/Pipeline/Palopegteriparatide (TransCon PTH)

Palopegteriparatide (TransCon PTH)

Hypoparathyroidism

Phase 3Met primary endpoint (Jan 2024); launched in Bo'ao Pilot Zone

Key Facts

Indication

Hypoparathyroidism

Phase

Phase 3

Status

Met primary endpoint (Jan 2024); launched in Bo'ao Pilot Zone

Company

A China-focused biopharma company developing long-acting endocrine therapies using TransCon technology.

Drug	Company	Phase	Status
Oral Long-Acting PTH Tablet	Opko Health	Preclinical	Active (Partnership with Entera Bio)
EB-612	Extend Biosciences	Phase 2	Active
Hypoparathyroidism Program	Confo Therapeutics	Discovery	Active
Canvuparatide (MBX 2109)	MBX Biosciences	Phase 2	Phase 2 (Avail trial) concluded May 2025; Phase 3 initiation planned for 2026.
SEP-479 (PTH1R)	Septerna	Phase 2	Active
EB612 (oral PTH(1-34))	Entera Bio	Phase 2	Active; Partnership with OPKO
Oral Long-Acting PTH	Entera Bio	Discovery/Preclinical	Active; Co-development with OPKO (Feb 2026)